DNA REPAIR ON THE FANCONI ANAEMIA PATHWAY
Associate Professor Wayne Crismani
Laboratory Head, DNA Repair & Recombination
St Vincent’s Institute of Medical Research,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | August 2025
Associate Professor Wayne Crismani is an internationally recognised expert in DNA repair, with a particular focus on Fanconi anaemia (FA)—a cancer-predisposition and bone marrow failure syndrome marked by extreme sensitivity to DNA damage. Based at St Vincent’s Institute in Melbourne, he leads a research program dedicated to understanding the genetic, cellular, and reproductive consequences of FA. He is currently supported by a Victorian Cancer Agency Mid-Career Fellowship and funding from the National Health and Medical Research Council.
His career spans academia and industry across Australia, Europe, and the United States. He has contributed to several advances in FA genetics, including the identification of new functions of FA genes, particularly in reproduction, development of isogenic cell models, and use of high-throughput functional and screening assays. He has also demonstrated that FA is under-diagnosed in Australia, which has major consequences for these individuals and for the public healthcare system. His research has been published in top-tier journals and underpins several patents, including technologies that have been successfully licensed.
Associate Professor Crismani also leads multidisciplinary studies investigating fertility and cancer risk in individuals with FA. These include the first systematic study of biological parenthood and assisted reproductive technologies in adults with FA, and efforts to identify early biomarkers of oral cancer in this high-risk group. His work is conducted in close collaboration with scientists, clinicians, fertility specialists, and patient advocates. He co-founded Fanconi Anaemia Support Australasia with a group of families in 2019 and continues to organise scientific and social events for the FA community.
He works with international FA registries, research consortia, and the Fanconi Cancer Foundation to ensure research findings inform real-world care. His program bridges molecular biology, reproductive health, and translational science, with the goal of improving health outcomes for people with FA and genetic conditions.
Source: Supplied
-
Impact of Leukaemia Foundation’s Research Funding into Blood Cancer
Bill Stavreski is the Head of Research at the Leukaemia Foundation who talks about the research impact in recent years. The Foundation itself marks its 25th anniversary in 2025, having funded a wide range of health and medical research since 2000. With a focus on basic science, health services research, treatment, and care, the organisation has invested nearly $90 million (adjusted in current dollars terms) in approximately 370 research grants over the years.
-
In his father’s footsteps as a kidney transplant specialist
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
